Program Committee

Andrew Zhu


Massachusetts General Hospital, Boston, MA

Dr. Andrew X. Zhu is a Professor of Medicine at Harvard Medical School and Director of Liver Cancer Research at Massachusetts General Hospital. Dr. Zhu is an internationally recognized leader in hepatocellular carcinoma and cholangiocarcinoma.  His clinical and research interests have focused on developing innovative therapies for hepatobiliary cancers, identifying novel molecular markers and genetic mutations, and dissecting the molecular mechanisms of drug resistance to targeted therapy in hepatobiliary cancers.   He has led the pivotal studies of developing several molecularly targeted and immunotherapy agents in hepatobiliary cancers.  He and his colleagues initially identified the presence of IDH mutations and the resistance mechanism to FGFR inhibitor in cholangiocarcinoma.